DataSheet_1_National expert consensus on home-administered oncologic therapies in Spain.pdf

The diagnosis and treatment of cancer impose a significant emotional and psychological burden on patients, families, and caregivers. Patients undergo several interventions in a hospital setting, and the increasing number of patients requiring extended care and follow-up is driving the demand for additional clinical resources to address their needs. Hospital at Home (HaH) teams have introduced home-administered oncologic therapies that represent a new model of patient-centered cancer care. This approach can be integrated with traditional models and offers benefits to both patients and healthcare professionals (HCPs). Home-administered treatment programs have been successfully piloted globally, demonstrated as a preferred option for most patients and a safe alternative that could reduce costs and hospital burden. The document aims to establish the minimum recommendations for the home administration of oncologic therapies (ODAH) based on a national expert agreement. The expert panel comprised seven leading members from diverse Spanish societies and three working areas: clinical and healthcare issues, logistical and administrative issues, and economic, social, and legal issues. The recommendations outlined in this article were obtained after a comprehensive literature review and thorough discussions. This document may serve as a basis for the future development of home-administered oncologic therapy programs in Spain.

癌症的诊疗会对患者、家属及照护者造成沉重的情感与心理负担。患者在医疗机构内需接受多项介入性诊疗操作，而需要长期照护与随访的患者数量持续增长，这推动了对更多临床资源的需求，以满足其相关照护需求。居家医院（Hospital at Home, HaH）团队推出了居家肿瘤治疗方案，这是一种以患者为中心的新型癌症照护模式。该模式可与传统诊疗体系融合，可为患者与医护人员（healthcare professionals, HCPs）带来多重益处。居家给药治疗方案已在全球范围内成功开展试点，被证实为多数患者的首选方案，同时也是一种可降低医疗成本、减轻医院负担的安全替代方案。本文件旨在基于全国专家共识，制定肿瘤治疗居家给药（home administration of oncologic therapies, ODAH）的最低推荐标准。专家组成员包括来自西班牙多个不同学会的7名核心成员，覆盖3个工作领域：临床与照护议题、物流与行政议题，以及经济、社会与法律议题。本文所概述的推荐意见，是在全面文献回顾与深入研讨后形成的。本文件可作为西班牙未来发展肿瘤治疗居家给药方案的基础。